Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials
Pascal Tétreault, Ali Mansour, Etienne Vachon-Presseau, Thomas J Schnitzer, A Vania Apkarian, Marwan N Baliki, Pascal Tétreault, Ali Mansour, Etienne Vachon-Presseau, Thomas J Schnitzer, A Vania Apkarian, Marwan N Baliki
Abstract
Placebo response in the clinical trial setting is poorly understood and alleged to be driven by statistical confounds, and its biological underpinnings are questioned. Here we identified and validated that clinical placebo response is predictable from resting-state functional magnetic-resonance-imaging (fMRI) brain connectivity. This also led to discovering a brain region predicting active drug response and demonstrating the adverse effect of active drug interfering with placebo analgesia. Chronic knee osteoarthritis (OA) pain patients (n = 56) underwent pretreatment brain scans in two clinical trials. Study 1 (n = 17) was a 2-wk single-blinded placebo pill trial. Study 2 (n = 39) was a 3-mo double-blinded randomized trial comparing placebo pill to duloxetine. Study 3, which was conducted in additional knee OA pain patients (n = 42), was observational. fMRI-derived brain connectivity maps in study 1 were contrasted between placebo responders and nonresponders and compared to healthy controls (n = 20). Study 2 validated the primary biomarker and identified a brain region predicting drug response. In both studies, approximately half of the participants exhibited analgesia with placebo treatment. In study 1, right midfrontal gyrus connectivity best identified placebo responders. In study 2, the same measure identified placebo responders (95% correct) and predicted the magnitude of placebo's effectiveness. By subtracting away linearly modeled placebo analgesia from duloxetine response, we uncovered in 6/19 participants a tendency of duloxetine enhancing predicted placebo response, while in another 6/19, we uncovered a tendency for duloxetine to diminish it. Moreover, the approach led to discovering that right parahippocampus gyrus connectivity predicts drug analgesia after correcting for modeled placebo-related analgesia. Our evidence is consistent with clinical placebo response having biological underpinnings and shows that the method can also reveal that active treatment in some patients diminishes modeled placebo-related analgesia. Trial Registration ClinicalTrials.gov NCT02903238 ClinicalTrials.gov NCT01558700.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
- de la Fuente-Fernández R, Schulzer M, Stoessl AJ. The placebo effect in neurological disorders. Lancet neurology. 2002;1(2):85–91. 10.1016/S1474-4422(02)00038-8 .
- Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annual review of pharmacology and toxicology. 2008;48:33–60. 10.1146/annurev.pharmtox.48.113006.094711 .
- Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract. 2011;11(1):33–41. 10.1111/j.1533-2500.2010.00401.x .
- Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69(2):374–9. 10.1136/ard.2009.107805
- Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115(3):254–63. 10.1016/j.pain.2005.02.032 .
- Finniss DG, Benedetti F. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain. 2005;114(1–2):3–6. 10.1016/j.pain.2004.12.012 .
- Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet. 2010;375(9715):686–95. 10.1016/S0140-6736(09)61706-2
- Hoffman GA, Harrington A, Fields HL. Pain and the placebo: what we have learned. Perspect Biol Med. 2005;48(2):248–65. 10.1353/pbm.2005.0054 .
- Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science (New York, NY). 2004;303(5661):1162–7. 10.1126/science.1093065 .
- Bingel U, Lorenz J, Schoell E, Weiller C, Büchel C. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain. 2006;120(1–2):8–15. 10.1016/j.pain.2005.08.027 .
- Peciña M, Stohler CS, Zubieta J-K. Neurobiology of placebo effects: expectations or learning? Social cognitive and affective neuroscience. 2014;9(7):1013–21. 10.1093/scan/nst079
- Benedetti F. Placebo effects: from the neurobiological paradigm to translational implications. Neuron. 2014;84(3):623–37. 10.1016/j.neuron.2014.10.023 .
- Wager TD, Atlas LY, Leotti LA, Rilling JK. Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain experience. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2011;31(2):439–52. 10.1523/JNEUROSCI.3420-10.2011
- Wager TD, Atlas LY, Lindquist MA, Roy M, Woo C-W, Kross E. An fMRI-based neurologic signature of physical pain. The New England journal of medicine. 2013;368(15):1388–97. 10.1056/NEJMoa1204471
- Baliki MN, Petre B, Torbey S, Herrmann KM, Huang L, Schnitzer TJ, et al. Corticostriatal functional connectivity predicts transition to chronic back pain. Nature neuroscience. 2012;15(8):1117–9. 10.1038/nn.3153
- Bassett DS, Wymbs NF, Porter MA, Mucha PJ, Carlson JM, Grafton ST. Dynamic reconfiguration of human brain networks during learning. Proc Natl Acad Sci U S A. 2011;108(18):7641–6. 10.1073/pnas.1018985108
- Langer N, Pedroni A, Gianotti LR, Hanggi J, Knoch D, Jancke L. Functional brain network efficiency predicts intelligence. Hum Brain Mapp. 2012;33(6):1393–406. 10.1002/hbm.21297 .
- Gabrieli JD, Ghosh SS, Whitfield-Gabrieli S. Prediction as a humanitarian and pragmatic contribution from human cognitive neuroscience. Neuron. 2015;85(1):11–26. 10.1016/j.neuron.2014.10.047
- Yu R, Gollub RL, Vangel M, Kaptchuk T, Smoller JW, Kong J. Placebo analgesia and reward processing: integrating genetics, personality, and intrinsic brain activity. Human brain mapping. 2014;35(9):4583–93. 10.1002/hbm.22496
- Apkarian AV, Bushnell MC, Treede R-D, Zubieta J-K. Human brain mechanisms of pain perception and regulation in health and disease. European journal of pain (London, England). 2005;9(4):463–84. 10.1016/j.ejpain.2004.11.001 .
- Hashmi JA, Baria AT, Baliki MN, Huang L, Schnitzer TJ, Apkarian AV. Brain networks predicting placebo analgesia in a clinical trial for chronic back pain. Pain. 2012. 10.1016/j.pain.2012.08.008
- Buchel C, Geuter S, Sprenger C, Eippert F. Placebo analgesia: a predictive coding perspective. Neuron. 2014;81(6):1223–39. 10.1016/j.neuron.2014.02.042 .
- Schmidt-Wilcke T, Ichesco E, Hampson JP, Kairys A, Peltier S, Harte S, et al. Resting state connectivity correlates with drug and placebo response in fibromyalgia patients. YNICL. 2014;6:252–61. 10.1016/j.nicl.2014.09.007
- Hall KT, Loscalzo J, Kaptchuk TJ. Genetics and the placebo effect: the placebome. Trends Mol Med. 2015;21(5):285–94. 10.1016/j.molmed.2015.02.009
- Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):448–57. 10.1056/NEJMra1201534 .
- Atlas LY, Whittington RA, Lindquist MA, Wielgosz J, Sonty N, Wager TD. Dissociable influences of opiates and expectations on pain. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2012;32(23):8053–64. 10.1523/JNEUROSCI.0383-12.2012
- Enck P, Klosterhalfen S, Weimer K, Horing B, Zipfel S. The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci. 2011;366(1572):1889–95. 10.1098/rstb.2010.0384
- Levine JD, Gordon NC, Smith R, Fields HL. Analgesic responses to morphine and placebo in individuals with postoperative pain. Pain. 1981;10(3):379–89. 10.1016/0304-3959(81)90099-3 .
- Zubieta J-K, Stohler CS. Neurobiological mechanisms of placebo responses. Annals of the New York Academy of Sciences. 2009;1156:198–210. 10.1111/j.1749-6632.2009.04424.x
- Peciña M, Zubieta J-K. Molecular mechanisms of placebo responses in humans. Molecular psychiatry. 2014. 10.1038/mp.2014.164 .
- Atlas LY, Wager TD. A meta-analysis of brain mechanisms of placebo analgesia: consistent findings and unanswered questions. Handbook of experimental pharmacology. 2014;225:37–69. 10.1007/978-3-662-44519-8_3 .
- Vase L, Vollert J, Finnerup NB, Miao X, Atkinson G, Marshall S, et al. Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials. Pain. 2015;156(9):1795–802. 10.1097/j.pain.0000000000000217 .
- Kaptchuk TJ, Miller FG. Placebo Effects in Medicine. N Engl J Med. 2015;373(1):8–9. 10.1056/NEJMp1504023 .
- Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999;19(1):484–94. .
- Benedetti F, Arduino C, Amanzio M. Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci. 1999;19(9):3639–48. .
- Petersen GL, Finnerup NB, Nørskov KN, Grosen K, Pilegaard HK, Benedetti F, et al. Placebo manipulations reduce hyperalgesia in neuropathic pain. Pain. 2012;153(6):1292–300. 10.1016/j.pain.2012.03.011 .
- Benedetti F, Carlino E, Pollo A. How placebos change the patient's brain. Neuropsychopharmacology. 2011;36(1):339–54. 10.1038/npp.2010.81
- Meissner K, Bingel U, Colloca L, Wager TD, Watson A, Flaten MA. The placebo effect: advances from different methodological approaches. J Neurosci. 2011;31(45):16117–24. 10.1523/JNEUROSCI.4099-11.2011
- Kaptchuk TJ, Kelley JM, Deykin A, Wayne PM, Lasagna LC, Epstein IO, et al. Do "placebo responders" exist? Contemp Clin Trials. 2008;29(4):587–95. 10.1016/j.cct.2008.02.002 .
- Yarkoni T, Poldrack RA, Nichols TE, Van Essen DC, Wager TD. Large-scale automated synthesis of human functional neuroimaging data. Nature methods. 2011;8(8):665–70. 10.1038/nmeth.1635
- Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg H, et al. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage. 2004;23 Suppl 1:S208–19. 10.1016/j.neuroimage.2004.07.051 .
- Achard S, Delon-Martin C, Vertes PE, Renard F, Schenck M, Schneider F, et al. Hubs of brain functional networks are radically reorganized in comatose patients. Proc Natl Acad Sci U S A. 2012;109(50):20608–13. Epub 2012/11/28. 10.1073/pnas.1208933109 1208933109 [pii].
- Achard S, Bullmore E. Efficiency and cost of economical brain functional networks. PLoS Comput Biol. 2007;3(2):e17 Epub 2007/02/06. 06-PLCB-RA-0424R2 [pii] 10.1371/journal.pcbi.0030017
- Rubinov M, Sporns O. Complex network measures of brain connectivity: uses and interpretations. NeuroImage. 2010;52(3):1059–69. 10.1016/j.neuroimage.2009.10.003 .
- Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. Neuroimage. 2014;92:381–97. 10.1016/j.neuroimage.2014.01.060
- Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36. 10.1148/radiology.143.1.7063747 .
Source: PubMed